Mobenakin - University of Maryland/Chiron Corporation/Otsuka Pharmaceuticals
Alternative Names: Interleukin-1 beta mutein; OCT 43Latest Information Update: 15 Aug 2007
Price :
$50 *
At a glance
- Originator University of Maryland, Baltimore
- Developer Chiron Corporation; Otsuka Pharmaceutical
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin-1beta replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Glioma; Lymphoma; Urogenital cancer
Most Recent Events
- 18 Feb 1997 Preregistration for Lymphoma in Japan (SC)
- 20 Nov 1995 OCT 43 is now called mobenakin
- 02 Nov 1995 Investigation in Glioma in Japan (SC)